Peptide Cancer Therapies
2 articles in this topic.
Peptide Cancer Therapies
Octreotide for Neuroendocrine Tumors
Octreotide LAR slowed NET progression by 58% in PROMID. How this somatostatin analog works, what the trials show, and where PRRT fits.
14 min read|Mar 25, 2026
Peptide Cancer Therapies
Somatostatin Analogs for Carcinoid Syndrome
Octreotide and lanreotide control carcinoid flushing and diarrhea in 50-70% of patients. Here's what the PROMID, CLARINET, and ELECT clinical trials showed.
15 min read|Mar 25, 2026